Related Experiment Video
Updated: May 13, 2026

07:26
Isolation and Characterization of Human Umbilical Cord-derived Mesenchymal Stem Cells from Preterm and Term Infants
Published on: January 26, 2019
Current and historical perspectives on methodological flaws in processing umbilical cord blood
1University of Cambridge, Cambridge, UK.
Transfusion
|February 26, 2013
Summary
Processing umbilical cord blood (UCB) hematopoietic stem cells (HSCs) using current methods can introduce artifacts and cell loss. Avoiding procedural flaws and temperature damage improves HSC yield for adult stem cell therapy.
Area of Science:
- Stem cell biology
- Hematopoietic stem cell transplantation
- Biomaterials science
Background:
- Umbilical cord blood (UCB) hematopoietic stem cells (HSCs) are crucial for treating various diseases.
- Current UCB processing methods, including HESPAN and Miltenyi particles, yield insufficient cells for adult treatment and introduce procedural artifacts.
- Temperature variations and processing reagents can damage HSCs, affecting their properties and leading to cell loss.
Purpose of the Study:
- To identify and highlight procedural flaws in UCB processing that affect HSC yield and viability.
- To suggest improvements in UCB processing to enhance the quality and quantity of HSCs for therapeutic applications.
- To address potential toxicity risks associated with current cell separation media.
Main Methods:
- Physicochemical and electrokinetic studies were conducted on UCB mononuclear cells (MNCs).
- Investigated the effects of delayed processing, temperature extremes (ice/freezing), and cell separation media on cell properties.
- Critically assessed current methods for isolating CD34+ cells, including positive selection with antibody-linked Miltenyi particles.
Main Results:
- Procedural artifacts, including biomaterial adsorption from cell damage and reagent degradation, were identified.
- Internalization of Miltenyi particles poses a potential toxicity risk due to iron accumulation.
- Optimized processing achieved approximately 5% yield of CD34+ cells, a significant advance for adult stem cell therapy.
Conclusions:
- Avoiding ice temperatures prevents platelet activation and subsequent biomaterial adsorption, preserving UCB-MNC/HSC properties.
- Omitting positive selection with Miltenyi particles avoids harsh reagents and potential toxicity hazards.
- Improved UCB processing methods offer a promising prospect for adult stem cell therapy using a single UCB donation.

